Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma

Table 1 Baseline characteristics of the patients with Ad-hepatocellular carcinoma who received camrelizumab plus apatinib and hepatic artery infusion chemotherapy therapy

Variables	Unmatched			PSM (1:1)
	TRIPLET alone group (n = 122)	TRIPLET-MWA group (n = 95)	P value	TRIPLET alone group (n = 82)	TRIPLET-MWA group (n = 82)	P value
Age, year			0.930			1.000
≤ 65	112 (91.80)	86 (90.53)		76 (92.68)	77 (93.90)
> 65	10 (8.20)	9 (9.47)		6 (7.32)	5 (6.10)	1.000
Gender			0.505
Female	12 (9.84)	13 (13.68)		8 (9.76)	9 (10.98)	1.000
Male	110 (90.16)	82 (86.32)		74 (90.24)	73 (89.02)
ECOG			0.900			1.000
0	122 (100.00)	94 (98.95)		82 (100.00)	81 (98.78)
1	0 (0.00)	1 (1.05)		0 (0.00)	1 (1.22)
Comorbidity			1.000			0.677
Absence	110 (90.16)	86 (90.53)		75 (91.46)	74 (90.24)
Presence	12 (9.84)	9 (9.47)		7 (8.54)	8 (9.76)
HBV			0.407			1.000
Absence	6 (4.92)	2 (2.11)		4 (4.88)	2 (2.44)
Presence	116 (94.26)	93 (95.79)		78 (95.12)	80 (97.56)
Ascites			0.011a			1.000
Absence	93 (76.23)	87 (91.58)		75 (91.46)	75 (91.46)
Presence	29 (22.95)	8 (8.42)		7 (8.54)	7 (8.54)
ALBI grade			0.041a			0.867
1	67 (54.92)	66 (69.47)		55 (67.07)	57 (69.51)
2-3	55 (45.08)	29 (30.53)		27 (32.93)	25 (30.49)
HCC number			0.277			0.219
1-3	54 (44.26)	50 (52.63)		50 (70.42)	42 (59.15)
> 3	68 (55.74)	45 (47.37)		21 (29.58)	29 (40.85)
HCC diameter, cm			0.667			0.155
< 5	7 (5.74)	6 (6.32)		7 (8.54)	4 (4.88)
5-10	51 (41.80)	34 (35.79)		41 (50.00)	32 (39.02)
> 10	64 (52.46)	55 (57.89)		34 (41.46)	46 (56.10)
AFP, ng/mL			0.605			0.428
≤ 400	46 (37.70)	40 (42.11)		31 (37.80)	37 (45.12)
> 400	76 (62.30)	55 (57.89)		51 (62.20)	45 (54.88)
Vascular invasion			0.077			0.346
Absence	18 (14.75)	24 (25.26)		15 (18.29)	21 (25.61)
Presence	104 (85.25)	71 (74.74)		67 (81.71)	61 (74.39)
Metastasis			0.750			0.158
Absence	68 (55.74)	50 (52.63)		50 (60.98)	40 (48.78)
Presence	54 (44.26)	45 (47.37)		32 (39.02)	42 (51.22)
AST ‎(U/L)‎, median, IQR	67 (31, 105)	77 (32, 112)	0.854	85 (28, 128)	77 (35, 127)	0.872
ALT ‎(U/L)‎‎, median, IQR	54 (22, 89)	59 (22, 89)	0.746	58 (22, 89)	59 (25, 109)	0.929
TBIL (μmol/L), mean ± SD	17.8	23.2	0.422	18.6	19.0	0.710
ALB (g/L), mean ± SD	37.0 ± 5.1	37.6 ± 4.2	0.564	37.2 ± 53	37.0 ± 4.2	0.567
INR, mean ± SD	1.1 ± 0.12	1.12 ± 0.10	0.901	1.10 ± 0.14	1.11 ± 0.10	0.892
PT (s), mean ± SD	12.4 ± 0.3	12.3 ± 0.6	0.940	12.4 ± 0.8	12.4 ± 0.6	1.000
PLT (× 109)‎, median, IQR	208(59, 245)	256 (67, 312)	0.358	230 (55, 270)	256 (78, 304)	0.660

^aP value < 0.05 suggest statistically significant differences.

Data are number of patients; data in parentheses are percentage unless otherwise indicated. Data in bracket was percent of patients. The quantitative data with mean ± SD or median with interquartile range were compared by the Kruskal-Wallis test. The qualitative data in two groups were compared by using the χ² test. HCC: Hepatocellular carcinoma; TRIPLET: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy; MWA: Microwave ablation; PSM: Propensity score match; ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; AFP: α-fetoprotein; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PT: Prothrombin time; INR: International normalized ratio; TBIL: Total bilirubin; PLT: Platelet; IQR: Interquartile range.